That might be somewhat priced in, they already have 2-73 patent and Aricept is generic. Its a given they get the patent so maybe a small pop is the most I would expect. BTW is that Auburn ?
USE " OT "- hoping it gets some attention now. But the other news
Data From METEOR Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Accepted as Late-Breaker Presentation in Presidential Session at European Cancer Congress 2015Business Wire(Mon, Aug 24) September 25-29, 2015, in Vienna, Austria
FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior TherapyBusiness Wire(Mon, Aug 24)
Very few people know the drug structure, not released and I don't recall , but I don't even think the drug manufacturer is known(?).
How do you think ACAD's drug will do as a Alzheimer's treatment. NUPLAZID is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors.
Hooperg...where is the best source to read up on the specific pathway that 2-73 affects, Sig1R ...how it unfolds proteins, various other reactions involved. Also, I was thinking that 2-73 might be similar to the small molecules of ITCI( ITI-007 for Schizophrenia ) and ACAD( structure already released Nuplazid/ pimavanserin for Parkinson's psychosis). TIA
Well here is your chance to make some serious cashola. I would say buying AVXL at $1.40 is like buying ACAD at $ 1.40 before its great run- Incredible opportunity. I am thinking 10,000 shares might get you that $1 mill in 3-5 yrs.
Well keep in mind the ACAD study was P3. Potential patient population only about 400,000 total MAX, ie that would be 100% penetration and that will never happen. The patient population of AD is a way bigger market. So in that respect AVXL news will have a greater impact on the share price than ACAD.
Look at ACAD 5 yr chart. It stayed at $1.60 for a while, moved up to $2.60 when only news of enrollment was issued. Then BOOM ! $5.20 with top line P3 data release for PIMA, a treatment for Parkinson's Disease Psychosis that affects about 40% of the 1mill Parkinson's US patient population. Great efficacy and safety, small molecule (sound familiar?). In fact ACAD will do an AD study also. But AVXL is ahead of ACAD with their AD study already showing greater efficacy than SOC and disease modifying - that is unique in the biotech sector after 10 yrs of failed AD studies. I think this is a scenario AVXL will follow. News will move this higher, data release, up listing, partnership, enrollment etc, many others. You don't want to be out of the stock when news hits. You will miss the big money.
Takes FDA up to 60 just to accept the NDA once its submitted, THEN if given Priority Review you then have to wait up to 6 months for the The Prescription Drug User Fee Act (PDUFA) date.
You forgot to mention all the news. And btw we are talking about a $5+ stock.
Data From METEOR Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Accepted as Late-Breaker Presentation in Presidential Session at European Cancer Congress 2015Business Wire(Mon 8:31AM EDT)
FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior TherapyBusiness Wire(Mon 8:30AM EDT)